Suppr超能文献

原发性肺癌和正常人体肺组织中催产素受体的表达模式

Oxytocin receptor pattern of expression in primary lung cancer and in normal human lung.

作者信息

Péqueux Christel, Breton Christophe, Hagelstein Marie-Thérèse, Geenen Vincent, Legros Jean-Jacques

机构信息

University of Liege, Institute of Pathology CHU-B23, +4, Center of Immunology & Laboratory of Neuroendocrinology, B-4000 Liege 1-Sart Tilman, Belgium.

出版信息

Lung Cancer. 2005 Nov;50(2):177-88. doi: 10.1016/j.lungcan.2005.05.027. Epub 2005 Jul 25.

Abstract

In order to assess if oxytocin- and vasopressin-induced mitogenic effects detected on small-cell lung carcinoma (SCLC) cell lines could be transposed on primary SCLC, the aim of the present work was to identify mediators of these mitogenic actions on primary tumours samples. This was addressed on normal human lung tissue, on SCLC and on non-SCLC (NSCLC). Herein, we observe, in normal human lung, that OTR is colocalized with vascular endothelial cells of the lung and is not expressed by lung cells of epithelial nature. We detected mRNA amplification of V1aR, V2R and of a V2R variant. We observed that 86% of SCLC biopsies analyzed expressed at least the OTR and that 71% expressed the OTR, the V1aR and the V2R altogether. Comparatively, 50% of NSCLC biopsies tested expressed at least the OTR and 32% expressed the OTR, the V1aR and the V2R altogether. The occurrence of the V1bR/V3R is of 28 and 18% for SCLC and NSCLC, respectively. Nevertheless, for the SCLC biopsies analyzed in this study, V1bR/V3R expression correlates, in all cases, with the expression of all the other neurohypophysial peptide receptors. Our results suggest that neurohypophysial peptide antagonists may offer promise as a potential new therapeutic modality for the treatment of lung cancer expressing at least one of the neurhypophysial peptide receptor subtypes.

摘要

为了评估在小细胞肺癌(SCLC)细胞系中检测到的催产素和加压素诱导的促有丝分裂作用是否可转化至原发性SCLC,本研究的目的是确定这些促有丝分裂作用在原发性肿瘤样本中的介质。这一研究在正常人类肺组织、SCLC和非小细胞肺癌(NSCLC)上进行。在此,我们观察到,在正常人类肺组织中,催产素受体(OTR)与肺血管内皮细胞共定位,而上皮性质的肺细胞不表达。我们检测到V1aR、V2R和一种V2R变体的mRNA扩增。我们观察到,分析的86%的SCLC活检样本至少表达OTR,71%同时表达OTR、V1aR和V2R。相比之下,50%检测的NSCLC活检样本至少表达OTR,32%同时表达OTR、V1aR和V2R。SCLC和NSCLC中V1bR/V3R的出现率分别为28%和18%。然而,对于本研究中分析的SCLC活检样本,在所有情况下,V1bR/V3R的表达都与所有其他神经垂体肽受体的表达相关。我们的结果表明,神经垂体肽拮抗剂可能有望成为治疗表达至少一种神经垂体肽受体亚型的肺癌的潜在新治疗方式。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验